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Bisphosphonates (BPs) are ligands for radioactive metal complexes used for imaging and therapeutic 
applications. The last BPs generation are heterocyclic nitrogen containing side chain such as 
risedronate and zoledronate. The aim of this study is to obtain new BPs derived from indazole with 
high biological and radiopharmaceutical potential activities. We report the synthesis and 
characterization of new indazolebisphosphonates (IDZBPs) substituted at different C- or N- positions 
of indazole rings, with the side chain with different lengths (1 to 5 carbon atoms from the 
bisphosphonate function to the nitrogen atom of the ring). IDZBPs are suitable for complexation with 
153Sm and the low energy electron emitters 177Lu and 47Sc. Radiochemicals tagged with low energy 
electron emitters are preferred because they are more likely to deliver a therapeutic dose to the 
bone and spare the bone marrow. Hydroxyapatite experiments, have shown that the highest binding 
values were obtained with [hydroxyl(1H-indazol-3-yl)methanediyl]bis(phosphonic acid) and 
[hydroxyl(1-methyl-1H-indazol-3-yl)methanediyl]bis(phosphonic acid) complexed by 153Sm, 177Lu 
and 46Sc. These selected potential radiopharmaceuticals were submitted to biodistribution studies. In
experiments, we use the scandium radioisotope 46Sc, instead of 47Sc because 47Sc is produced using
fast neutrons via the reaction 47Ti (n,p)47Sc, which is not easily accessible to us, while 46Sc is 
producing by direct neutron irradiation of scandium. 153Sm and 177Lu were respectively produced by 
direct neutron irradiation of enriched samarium (98%) and natural lutetium oxides. A slight change 
between the two ligands - the free N-H position substituted by a methyl group - results in a distinct 
radiopharmacokinetic. These experiments confirm that a single change in the chemical structure 
plays a decisive role in binding to hydroxyapatite, as well in bone uptake. Acknowledgements: This 
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